George Petrocheilos
Co-Founder & Managing Partner @ Catalio Capital Management
George Petrocheilos is a Series A investor at Catalio Capital Management focused on Biotechnology and Life Science. George Petrocheilos is the President at HealthCor Catalio Acquisition. George Petrocheilos attended The Johns Hopkins University.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 90%
Last updated:
For AI agents: llms.txt
Industries George Petrocheilos invests in
Stages George Petrocheilos invests in
Countries George Petrocheilos invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 8 (80%)
- Life Science 5 (50%)
- Medical 4 (40%)
- Therapeutics 3 (30%)
- Health Care 2 (20%)
Stage
- Series A 5 (50%)
- Series B 2 (20%)
- Series C 1 (10%)
Country
- United States 6 (60%)
- France 1 (10%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Clasp Therapeutics offers to reach of immuno-oncology with novel precision medicines that enable the immune system to identify and specifically destroy hard-to-treat tumors bearing common driver mutations, regardless of tumor type. | $150M / Series A / Mar 20, 2024 | ||
| Haystack Oncology, an oncology company, uses the most recent circulating tumor DNA detection technology to enhance the diagnosis of minimum residual disease and provide superior therapy decision-making information. | $56M / Series A / Nov 16, 2022 | ||
| Anagenex is a seed stage biotechnology company building a novel platform for drug discovery focusing on difficult targets. | $30M / Series A / Jun 08, 2022 | ||
| Pheast Therapeutics is a cancer immunotherapy company focused on developing novel checkpoint therapies to harness the innate immune system in the fight against cancer. It was founded in 2020 and headquartered in Palo Alto, California. | $76M / Series A / Apr 26, 2022 | ||
| Octant Bio is a developer of synthetic technology used to improve health and treat disease. Its technology uses synthetic biology, genome engineering, next-generation sequencing, and computational tools to simultaneously measure the activity of thousands of receptor pathways in human cells that enable scientists to apply machine learning methods toengineer small molecules that interact with multiple receptors and unlock a new potential to treat complex diseases. | $80M / Series B / Apr 21, 2022 | ||
| DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Their revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results. | $35M / Series C / Jan 04, 2022 | ||
| DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Their revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results. | $165M / Series C / Oct 26, 2021 | ||
| Sensei Biotherapeutics is a clinical-stage biotechnology company specializing in the field of next-generation cancer immunotherapies. The company developing novel biologics therapies targeting key components of the immune system for the treatment of cancers of unmet need. They are also focused on the discovery, development, and delivery ofmedicines that alter the treatment landscape and contributing value to patients and society.Sensei Biotherapeutics using its proprietary drug discovery platform to study and understand the tumor microenvironment and identify a new class of cancer immunotherapies that act through new biology and differentiated mechanisms. It brings together scientific leaders in biology, immunology, and oncology along with a highly experienced management team and scientific advisors. The company's platform, ImmunoPhage enables the generation of immune-activating agents that fully engage activation of both the innate and adaptive immune systems. Sensei Biotherapeutics is headquartered in Gaithersburg, Maryland with an office in Boston, MA, USA. | $30M / Series B / Jan 11, 2021 | ||
| Spiral Therapeutics develops biopharmaceutical therapies focused on treating inner ear disorders, including hearing loss, balance disorders, and related auditory conditions. The company operates as a clinical-stage drug developer, advancing a pipeline of therapeutics designed to address conditions with limited or no approved treatment options. Itscore approach combines proprietary drug formulations with targeted delivery technologies that enable precise and sustained administration of therapeutics directly to the cochlea. This method is designed to improve treatment effectiveness by delivering drugs to specific areas of the inner ear while minimizing systemic exposure.Spiral Therapeutics focuses on developing small-molecule therapies and sustained-release formulations that address inflammation and other underlying causes of inner ear disorders. Its lead programs include treatments for conditions such as Ménière’s disease, where symptoms like vertigo, tinnitus, and hearing loss are linked to inner ear dysfunction. | $5.6M / Series A / Dec 12, 2018 | ||
| See all 10 investments → | |||
Co-Investors
Catalio Capital Management is a venture capital firm that invests in breakthrough biomedical technology companies.
Catalio Capital Management Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Ben Snedeker
Partner and Co-Head Public Equities
|
|||
|
George Petrocheilos
Co-Founder & Managing Partner
|
|||
Isaac Ro
Partner
|
|||
Jacob Vogelstein
Co-Founder and Managing Partner
|
|||
Kenan Turnacioglu
General Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does George Petrocheilos invest in?
George Petrocheilos invests primarily in Biotechnology, Life Science and Medical startups, most often at Series A and Series B stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact George Petrocheilos?
Public channels for George Petrocheilos include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did George Petrocheilos last invest?
The most recent investment recorded for George Petrocheilos closed in Mar 2024. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
